Skip to content
value.today
Total raised
$45 M
1 round on record
Latest round
$45 M
Jun 2016
First round on record
Jun 2016
Today
Went public
See the company page

Verona Pharma plc is listed today as Verona Pharma plc: market value, financials and filings are on its company page.

Funding rounds

1 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Verona Pharma plc
MonthRaisedRaiseSizeInvestorsSoldFiling
Jul 2020$200 MPrivate placement after listing$50 to $250 million

Verona Pharma plc: Private sale, Jul 2020

Investors in this round

43 investors had bought by the notice of Jul 30, 2020: 43 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$200 M of $200 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$12,000,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in United Kingdom

People named in the notice

  • Claire W. Poll · Executive Officer
  • David Zaccardelli · Executive Officer, Director
  • Kathleen W. Rickard · Executive Officer
  • Mark W. Hahn · Executive Officer
  • Anders W. Ullman · Director
  • Andrew W. Sinclair · Director
  • David W. Ebsworth · Director
  • Ken W. Cunningham · Director
  • Mahendra W. Shah · Director
  • Martin W. Edwards · Director
  • Rishi W. Gupta · Director
  • Vikas W. Sinha · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • JEFFERIES LLC (CRD 2347) · New York, New YorkSold in all US states
  • CANACCORD GENUITY LLC (CRD 1020) · New York, New YorkSold in all US states
  • WEDBUSH SECURITIES INC. (CRD 877) · Los Angeles, CaliforniaSold in all US states
  • BTIG, LLC (CRD 122225) · San Francisco, CaliforniaSold in all US states

Signed by Mark Hahn, Chief Financial Officer. Source: SEC Form D, newest notice filed Jul 30, 2020. Read the notice at the SEC.

equitySEC
Jun 2016$45 MNo. 1$10 to $50 million

Verona Pharma plc: Raise no. 1, Jun 2016

Investors in this round

8 investors had bought by the notice of Jul 20, 2016: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$45 M of $45 M offered
Smallest investment taken
$420,995
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$2,892,788
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in United Kingdom

People named in the notice

  • Jan-Anders Karlsson · Executive Officer, Director
  • Kenneth Newman · Executive Officer
  • Peter Spargo · Executive Officer
  • Anders Ullman · Director
  • David Ebsworth · Director
  • Ken Cunningham · Director
  • Patrick Humphrey · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • MTS SECURITIES, LLC (CRD 104059) · New York, New YorkSold in CA, MA, MD, NY

Remarks in the notice

  • On the amounts: “Based on exchange rate GBP 1.00 to USD 1.324889.”

Signed by Jan-Anders Karlsson, Chief Executive Officer. Source: SEC Form D, newest notice filed Jul 20, 2016. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Verona Pharma plc chose not to state its revenue in its newest notice of a funding round (Jul 2020).

    SEC Form D · Jul 2020

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Jul 2020

That is all the official record says: Verona Pharma plc has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Verona Pharma plc are on record.

Investors#

No investor of Verona Pharma plc is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 8 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Verona Pharma plc
NameRoleNamed in
Claire W. PollExecutive officerJul 2020
David ZaccardelliExecutive officerJul 2020
Kathleen W. RickardExecutive officerJul 2020
Mark W. HahnExecutive officerJul 2020
Jan-Anders KarlssonExecutive officerJul 2016
Kenneth NewmanExecutive officerJul 2016
Peter SpargoExecutive officerJul 2016
Anders W. UllmanDirectorJul 2020
Andrew W. SinclairDirectorJul 2020
David W. EbsworthDirectorJul 2020
David ZaccardelliDirectorJul 2020
Ken W. CunninghamDirectorJul 2020
Mahendra W. ShahDirectorJul 2020
Martin W. EdwardsDirectorJul 2020
Rishi W. GuptaDirectorJul 2020
Vikas W. SinhaDirectorJul 2020
Anders UllmanDirectorJul 2016
David EbsworthDirectorJul 2016
Jan-Anders KarlssonDirectorJul 2016
Ken CunninghamDirectorJul 2016
Patrick HumphreyDirectorJul 2016

About

Company in London, United Kingdom.

Went public since 2017. Its SEC number is that of a company listed on a stock exchange.